source
- FDA denies Summit Therapeutics' ivonescimab for EGFR-mutated lung cancer, halting US entryThe U.S. Food and Drug Administration issued a complete response letter rejecting Summit Therapeutics' biologics license application for ivonescimab, a PD-1xVEGF bispecific antibody intended for EG…
- PharmaLogic acquires Lantheus radiopharma CDMO and New Jersey plant to launch transatlantic manufacturing platformPharmaLogic announced it will purchase Lantheus' radiopharmaceutical contract development and manufacturing organization (CDMO) along with a production plant in Springfield, New Jersey. Lantheus h…